124 related articles for article (PubMed ID: 37651769)
1. Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Bive BZ; Sacheli R; Mudogo CN; Zakayi PK; Bontems S; Lelo GM; Hayette MP
J Mycol Med; 2023 Nov; 33(4):101428. PubMed ID: 37651769
[TBL] [Abstract][Full Text] [Related]
2. Clinical epidemiology and high genetic diversity amongst Cryptococcus spp. isolates infecting people living with HIV in Kinshasa, Democratic Republic of Congo.
Bive BZ; Sacheli R; Situakibanza Nani-Tuma H; Kabututu Zakayi P; Ka A; Mbula Mambimbi M; Muendele G; Boreux R; Landu N; Nzanzu Mudogo C; M'Buze PR; Moutschen M; Meyer W; Mvumbi Lelo G; Hayette MP
PLoS One; 2022; 17(5):e0267842. PubMed ID: 35587939
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
4. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
6. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
7. Reduced Susceptibility to Azoles in Cryptococcus gattii Correlates with the Substitution R258L in a Substrate Recognition Site of the Lanosterol 14-α-Demethylase.
Carvajal SK; Melendres J; Escandón P; Firacative C
Microbiol Spectr; 2023 Aug; 11(4):e0140323. PubMed ID: 37341584
[TBL] [Abstract][Full Text] [Related]
8. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
10. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
11. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
Lee GA; Arthur I; Merritt A; Leung M
Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
13. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
[TBL] [Abstract][Full Text] [Related]
14.
Pharkjaksu S; Chongtrakool P; Chayakulkeeree M; Mitrpant C; Angkasekwinai P; Bennett JE; Kwon-Chung KJ; Ngamskulrungroj P
Infect Drug Resist; 2020; 13():673-681. PubMed ID: 32161475
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends in antifungal susceptibility of Cryptococcus neoformans isolates from a reference laboratory in the United States, 2011-2021.
Ordaya EE; Abu Saleh OM; Vergidis P; Deml SM; Wengenack NL; Fida M
Mycoses; 2024 Jan; 67(1):e13691. PubMed ID: 38214377
[TBL] [Abstract][Full Text] [Related]
16. Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.
Gast CE; Basso LR; Bruzual I; Wong B
Antimicrob Agents Chemother; 2013 Nov; 57(11):5478-85. PubMed ID: 23979758
[TBL] [Abstract][Full Text] [Related]
17. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
18. Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China.
Fan X; Xiao M; Chen S; Kong F; Dou HT; Wang H; Xiao YL; Kang M; Sun ZY; Hu ZD; Wan Z; Chen SL; Liao K; Chu YZ; Hu TS; Zou GL; Hou X; Zhang L; Zhao YP; Xu YC; Liu ZY
Clin Microbiol Infect; 2016 Oct; 22(10):887.e1-887.e9. PubMed ID: 27432767
[TBL] [Abstract][Full Text] [Related]
19. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
Arechavala AI; Ochiuzzi ME; Borgnia MD; Santiso GM
Rev Iberoam Micol; 2009 Sep; 26(3):194-7. PubMed ID: 19635445
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
